Scarica l'app Stockscreener
18.80
10.94%
1.84
Urogen Pharma Ltd Borsa (URGN) Ultime notizie
Is UroGen Pharma Ltd. a good long term investmentFree Stock Market Knowledge Sharing - Autocar Professional
What analysts say about UroGen Pharma Ltd. stockFree Predictions - Autocar Professional
What drives UroGen Pharma Ltd. stock priceSuperior returns - jammulinksnews.com
INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of - GlobeNewswire
UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit - GlobeNewswire Inc.
UroGen Pharma Ltd. Stock Analysis and ForecastFree High-Return Strategy Alerts - Autocar Professional
UroGen Pharma Announces Data Of Phase 2b Of Bladder Cancer Study - Nasdaq
UroGen Pharma (URGN) Reports Long-term Results for Bladder Cance - GuruFocus
UroGen’s bladder cancer drug shows durable response in long-term study - Investing.com Australia
UroGen Pharma Announces Long-Term Efficacy Results of ZUSDURI for Non-Muscle Invasive Bladder Cancer in Clinical Genitourinary Cancer Journal - Quiver Quantitative
UroGen Announces Five-Year Long-Term Extension Study of the - GlobeNewswire
Breakthrough: New Bladder Cancer Treatment Maintains Effectiveness for 3.5 Years Without Surgery - Stock Titan
2025-07-20 | URGN Shareholders Have Opportunity to Lead UroGen Pharma Ltd. Class Action LawsuitContact Bronstein, Gewirtz and Grossman, LLC Today! | NDAQ:URGN | Press Release - Stockhouse
UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors - GlobeNewswire
Urogen Pharma (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts - Defense World
UroGen Bets Big On Gel-Based Cancer Treatments - Finimize
URGN Class Action News: UroGen Pharma Ltd. Investors with - GlobeNewswire
2025-07-17 | URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:URGN | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming DeadlinesURGN - ETX View
UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors - GlobeNewswire
What makes UroGen Pharma Ltd. stock price move sharplyBreakout Setup Scanner - beatles.ru
2025-07-14 | URGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! | NDAQ:URGN | Press Release - Stockhouse
What UroGen Pharma Ltd.'s (NASDAQ:URGN) 84% Share Price Gain Is Not Telling You - 富途牛牛
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the Firm - GlobeNewswire
Urogen Pharma's (URGN) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Lowey Dannenberg Notifies UroGen Pharma Ltd. (“UroGen” or - GlobeNewswire
UroGen bladder cancer drug mitomycin wins FDA approval - MSN
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN) - 富途牛牛
UroGen Pharma stock holds Buy rating at H.C. Wainwright on Phase 3 trial progress By Investing.com - Investing.com South Africa
UroGen Pharma stock holds Buy rating at H.C. Wainwright on Phase 3 trial progress - Investing.com India
UroGen concludes enrolment in Phase III trial of UGN-103 for bladder cancer - Yahoo Finance
Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking - simplywall.st
URGN: Analyst Reiterates Buy Rating with $25 Price Target | URGN Stock News - GuruFocus
UroGen completes enrollment in phase 3 bladder cancer trial By Investing.com - Investing.com India
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA - GuruFocus
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | URGN Stock New - GuruFocus
4.56%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):